ACLX

Arcellx

Fundamental data last updated:April 13, 2026

We may earn a commission from partner links. This content is for informational purposes only and is not financial advice. Information may be delayed or inaccurate.

company profile

SECTOR

Healthcare

industry

Biotechnology

Exchange

Nasdaq

County of HQ

United States

Next Earnings Date

05/14/26

Business Summary

Arcellx is a clinical-stage biotechnology company focused on developing cell therapies, likely targeting oncology indications through engineered immune cell platforms. Its business model centers on investing heavily in research and clinical trials to create proprietary therapeutic candidates, then monetizing through commercialization or strategic partnerships. Cash generation, when it occurs, will come from milestone payments, licensing agreements, and eventual product sales following regulatory approval. The moat, if realized, would stem from proprietary cell engineering platforms, intellectual property protection, and regulatory exclusivity — but until commercialization, the moat is entirely potential rather than proven.

 


Analyze ACLX on TradingView

VALUATION

P/E

-

Market Cap ($M USD)

$6,715

Forward P/E

-

PEG

-

PRICE TO SALES

294.1

PRICE TO BOOK

16.7

EV / EBITDA

-28.4

5-Year Average P/E

Free Cash Flow Yield

DCF Value

Graham Number

Price to FCF

EV to FCF

Earnings Yield

FCF Yield

DIVIDEND

Yield

-

Annual Payout

-

Payout Ratio

-

Consecutive Years of Dividend Growth

0

5-Year Dividend Growth Rate

-

Financial Health & Profitability

Earnings Per Share

-$4.07

Next Year EPS Growth Estimate

-$1.73

Next Year Revenue Growth Estimate

259.20%

Return on Equity (ROE)

-56.90%

FREE CASH FLOW

Operating Margin

-1135.60%

Debt-to-Equity

0.1

Piotroski F-Score

1

Altman Z-Score

17.7

Return on Invested Capital (ROIC)

-52.60%

Current Ratio

4.4

Quick Ratio

Net Debt to EBITDA

Interest Coverage

Gross Profit margin

FCF PER SHARE

REVENUE PER SHARE

Analyze ACLX on TradingView

Gainseekers Quantitative Analysis

Summary

This is a pure balance-sheet story wrapped around a cash-burning biotech. With no P/E, no Forward P/E, EPS at -28.4, and operating margins at -56.90%, this is not a valuation-driven equity — it is a capital markets vehicle. However, the Altman Z-Score of 17.7 and Current Ratio of 4.4 signal extremely low near-term bankruptcy risk despite deeply negative profitability metrics. The market is clearly pricing in speculative future optionality given the extreme Price/Sales of 294.1 and Price/Book of 16.7, meaning this is neither mispriced value nor GARP — it is a high-volatility clinical-stage bet with liquidity support but no earnings foundation.

AI Exposure / Tech Reliance

As a Biotechnology company in Healthcare, its long-term competitiveness depends on R&D efficiency and data-driven clinical execution. AI-driven drug discovery and biomarker modeling are increasingly central to biotech pipelines, which could improve capital efficiency over time. However, with current negative margins and no earnings visibility, technological adaptation alone does not solve its fundamental cash burn profile.

The Bull Case

A speculative institutional bull would focus on survivability and optionality. The Altman Z-Score of 17.7 combined with a Current Ratio of 4.4 implies strong liquidity and minimal near-term insolvency risk — critical in biotech. Despite a dreadful Piotroski F-Score of 1 and ROIC of -52.60%, bulls would argue that early-stage biotech metrics always look optically terrible before commercialization, and the 259.20% Return on Equity suggests aggressive capital structure dynamics that could amplify upside if clinical milestones are met. With a $6,715M market cap, the company clearly has institutional sponsorship and access to capital, positioning it to fund pipeline progress without immediate financial distress.

The Bear Case

The bear case is overwhelming on fundamentals. Debt/Equity at -1135.60% reflects extreme capital structure distortion, ROIC at -52.60% signals catastrophic capital inefficiency, and operating margins of -56.90% confirm ongoing heavy cash burn. EPS of -28.4 with next year estimated at -4.07 shows losses narrowing but still deeply negative, and the absence of any P/E or Forward P/E eliminates valuation anchoring. A Piotroski F-Score of 1 is near the bottom of the quality spectrum, suggesting deteriorating financial strength — this is structurally weak and entirely dependent on future clinical success rather than current economics.

Market Sentiment & Smart Money

Short Interest %

10.90%

Analyst Consensus

2.89

Average Analyst Price Target

$104.15

Institutional Ownership %

90.00%

1-Year Beta

-0.16

Insider Buying % (6 Mo)

12.90%%

Distance to 52-Week High

99.90%

Distance to 52-Week Low

239.90%

EARNINGS SURPRISE %

50-DAY SMA

200-DAY SMA

⚠️ Financial Disclaimer:
This content is for informational purposes only and is not financial advice. Information may be delayed or inaccurate. We may earn a commission from partner links.